A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Status:	Active, not recruiting
Conditions:	Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/5/2019
Start Date:	June 7, 2017
End Date:	August 30, 2020

Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors

The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab
is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast
Cancers, that have advanced or have spread.

Inclusion Criteria:

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

- Patients with metastatic or advanced solid tumors

- Women with histologically or cytologically confirmed triple negative breast carcinoma

- Participants with histologically or cytologically confirmed pancreatic adenocarcinoma

- Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer
(NSCLC)

Exclusion Criteria:

- Active brain metastases or leptomeningeal metastases.

- Any serious or uncontrolled medical disorder

- Prior malignancy active within the previous 3 years

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

Providence Portland Medical Center

4805 Northeast Glisan Street
Portland, Oregon 97213

(503) 215-1111